表紙
市場調查報告書

黃斑部病變治療市場:全球產業分析,規模,佔有率,成長,趨勢,預測

Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

出版商 Transparency Market Research 商品編碼 799197
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
黃斑部病變治療市場:全球產業分析,規模,佔有率,成長,趨勢,預測 Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日期: 2019年02月15日內容資訊: 英文 195 Pages
簡介

本報告提供全球黃斑部病變治療市場相關調查,彙整市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 市場分析與預測

第5章 主要考察

  • 法律規章方案
  • 合併·收購
  • 老年性黃斑部病變臨床實驗分析
  • 償付方案
  • 老年性黃斑部病變罹患率

第6章 各疾病適應症市場分析與預測

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 溼性黃斑部病變
    • 乾性黃斑部病變
    • 其他
  • 市場魅力度

第7章 各類藥物市場分析與預測

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 抗血管內皮層生長因子
    • 其他
  • 市場魅力度

第8章 各流通管道市場分析與預測

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 醫院
    • 眼科診所
    • 門診外科中心
  • 市場魅力度

第9章 各地區市場分析與預測

  • 主要調查結果
  • 市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力度

第10章 北美市場

第11章 歐洲市場

第12章 亞太地區市場

第13章 南美市場

第14章 中東·非洲市場

第15章 競爭環境

  • 企業市場佔有率分析與競爭矩陣
  • 企業簡介

圖表

目錄

Title:
Macular Degeneration Treatment Market (Disease Indication - Dry Age related Macular Degeneration (dAMD), Wet Age-related Macular Degeneration (wAMD); Drug Class - Anti Vascular Endothelial Growth Factor and Others; Distribution Channel - Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Macular Degeneration Treatment Market: Overview

This report on the global macular degeneration treatment market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on disease indication, drug class, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and company profiles with business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global macular degeneration treatment market.

Global Macular Degeneration Treatment Market: Key Segments

Based on disease indication, the global macular degeneration treatment market has been segmented into dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), and others. In terms of drug class, the market has been classified into anti-vascular endothelial growth factor and others. Based on distribution channel, the market has been categorized into hospitals, ophthalmic clinics, and ambulatory surgical centers. The global macular degeneration treatment market has been analyzed based on increasing regulatory scrutiny, technology trends, expenditure on emerging technologies, pipeline molecules and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Macular Degeneration Treatment Market: Regional Outlook

In terms of region, the global macular degeneration treatment market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period of 2016 to 2026, along with their respective CAGRs for the forecast period 2018-2026, considering 2017 as the base year.

Companies Mentioned in the Report

The report profiles major players operating in the global macular degeneration treatment market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report include Allergan, Inc., Pfizer, Inc., Novartis AG., REGENERON PHARMACEUTICALS, INC., Santen Pharmaceuticals, Valeant Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sanofi, and Bayer AG.

The global macular degeneration treatment market has been segmented as follows:

Global Macular Degeneration Treatment Market, by Disease Indication

  • Wet age-related macular degeneration
  • Dry age-related macular degeneration
  • Others

Global Macular Degeneration Treatment Market, by Drug Class

  • Anti-vascular endothelial growth factor
  • Others

Global Macular Degeneration Treatment Market, by Distribution Channel

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Global Macular Degeneration Treatment Market, by Region

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia & New Zealand
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Macular Degeneration Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Disease Indication Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
      • 4.3.1.1. Growing prevalence of AMD owing to increase in the geriatric population
      • 4.3.1.2. Increase in health care spending and improvement in health care infrastructure
      • 4.3.1.3. New product launches and high annual cost of therapy (ACOT)
      • 4.3.1.4. Rise in number of eye care centers leading to increased product utilization
    • 4.3.2. Restraints
      • 4.3.2.1. Patent expiry of three well-established anti-VEGFs
      • 4.3.2.2. Non-compliance with treatment
      • 4.3.2.3. Lack of awareness
    • 4.3.3. Opportunities
  • 4.4. Global Macular Degeneration Treatment Market Analysis and Forecast, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insight

  • 5.1. Regulatory Scenario by Region/Globally
  • 5.2. Key Mergers & Acquisitions
  • 5.3. AMD Clinical Trial Analysis
  • 5.4. Reimbursement Scenario
  • 5.5. AMD Prevalence Rate Globally with Key Countries

6. Global Macular Degeneration Treatment Market Analysis and Forecast, by Disease Indication

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
    • 6.3.1. Wet age-related macular degeneration
    • 6.3.2. Dry age-related macular degeneration
    • 6.3.3. Others
  • 6.4. Global Macular Degeneration Treatment Market Attractiveness, by Disease Indication

7. Global Macular Degeneration Treatment Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
    • 7.3.1. Anti-vascular endothelial growth factor
    • 7.3.2. Others
  • 7.4. Global Macular Degeneration Treatment Market Attractiveness, by Drug Class

8. Global Macular Degeneration Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
    • 8.3.1. Hospitals
    • 8.3.2. Ophthalmic Clinics
    • 8.3.3. Ambulatory Surgical Centers
  • 8.4. Global Macular Degeneration Treatment Market Attractiveness, by Distribution Channel

9. Global Macular Degeneration Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Macular Degeneration Treatment Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Global Macular Degeneration Treatment Market Attractiveness, by Region

10. North America Macular Degeneration Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
    • 10.2.1. Wet age-related macular degeneration
    • 10.2.2. Dry age-related macular degeneration
    • 10.2.3. Others
  • 10.3. North America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
    • 10.3.1. Anti-vascular endothelial growth factor
    • 10.3.2. Others
  • 10.4. North America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.4.1. Hospitals
    • 10.4.2. Ophthalmic Clinics
    • 10.4.3. Ambulatory Surgical Centers
  • 10.5. North America Macular Degeneration Treatment Market Value Forecast, by Country, 2016-2026
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Macular Degeneration Treatment Market Attractiveness Analysis
    • 10.6.1. By Disease Indication
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Macular Degeneration Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
    • 11.2.1. Wet age-related macular degeneration
    • 11.2.2. Dry age-related macular degeneration
    • 11.2.3. Others
  • 11.3. Europe Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
    • 11.3.1. Anti-vascular endothelial growth factor
    • 11.3.2. Others
  • 11.4. Europe Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.4.1. Hospitals
    • 11.4.2. Ophthalmic Clinics
    • 11.4.3. Ambulatory Surgical Centers
  • 11.5. Europe Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016-2026
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Europe Macular Degeneration Treatment Market Attractiveness Analysis
    • 11.6.1. By Disease Indication
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Macular Degeneration Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
    • 12.2.1. Wet age-related macular degeneration
    • 12.2.2. Dry age-related macular degeneration
    • 12.2.3. Others
  • 12.3. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
    • 12.3.1. Anti-vascular endothelial growth factor
    • 12.3.2. Others
  • 12.4. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.4.1. Hospitals
    • 12.4.2. Ophthalmic Clinics
    • 12.4.3. Ambulatory Surgical Centers
  • 12.5. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016-2026
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis
    • 12.6.1. By Disease Indication
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Macular Degeneration Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Latin America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
    • 13.2.1. Wet age-related macular degeneration
    • 13.2.2. Dry age-related macular degeneration
    • 13.2.3. Others
  • 13.3. Latin America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
    • 13.3.1. Anti-vascular endothelial growth factor
    • 13.3.2. Others
  • 13.4. Latin America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.4.1. Hospitals
    • 13.4.2. Ophthalmic Clinics
    • 13.4.3. Ambulatory Surgical Centers
  • 13.5. Latin America Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016-2026
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Macular Degeneration Treatment Market Attractiveness Analysis
    • 13.6.1. By Disease Indication
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Macular Degeneration Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
    • 14.2.1. Wet age-related macular degeneration
    • 14.2.2. Dry age-related macular degeneration
    • 14.2.3. Others
  • 14.3. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
    • 14.3.1. Anti-vascular endothelial growth factor
    • 14.3.2. Others
  • 14.4. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
    • 14.4.1. Hospitals
    • 14.4.2. Ophthalmic Clinics
    • 14.4.3. Ambulatory Surgical Centers
  • 14.5. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016-2026
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis
    • 14.6.1. By Disease Indication
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Market Share Analysis by Company & Competition Matrix (By Tier and Size of companies)
  • 15.2. Company Profiles
    • 15.2.1. Allergan plc.
      • 15.2.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.1.2. Business Overview
      • 15.2.1.3. Product Portfolio
      • 15.2.1.4. Financial Overview
      • 15.2.1.5. SWOT Analysis
    • 15.2.2. Novartis AG
      • 15.2.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.2.2. Business Overview
      • 15.2.2.3. Product Portfolio
      • 15.2.2.4. Financial Overview
      • 15.2.2.5. SWOT Analysis
    • 15.2.3. Pfizer Inc.
      • 15.2.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.3.2. Business Overview
      • 15.2.3.3. Product Portfolio
      • 15.2.3.4. Financial Overview
      • 15.2.3.5. SWOT Analysis
    • 15.2.4. Santen Pharmaceuticals Co. Ltd.
      • 15.2.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.4.2. Business Overview
      • 15.2.4.3. Product Portfolio
      • 15.2.4.4. Financial Overview
      • 15.2.4.5. SWOT Analysis
    • 15.2.5. Valeant Pharmaceuticals International, Inc.
      • 15.2.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.5.2. Business Overview
      • 15.2.5.3. Product Portfolio
      • 15.2.5.4. Financial Overview
      • 15.2.5.5. SWOT Analysis
    • 15.2.6. Bayer AG
      • 15.2.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.6.2. Business Overview
      • 15.2.6.3. Product Portfolio
      • 15.2.6.4. Financial Overview
      • 15.2.6.5. SWOT Analysis
    • 15.2.7. F. Hoffmann-La Roche Ltd.
      • 15.2.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.7.2. Business Overview
      • 15.2.7.3. Product Portfolio
      • 15.2.7.4. Financial Overview
      • 15.2.7.5. SWOT Analysis
    • 15.2.8. Sanofi
      • 15.2.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.8.2. Business Overview
      • 15.2.8.3. Product Portfolio
      • 15.2.8.4. Financial Overview
      • 15.2.8.5. SWOT Analysis
    • 15.2.9. REGENERON PHARMACEUTICALS, INC.
      • 15.2.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 15.2.9.2. Business Overview
      • 15.2.9.3. Product Portfolio
      • 15.2.9.4. Financial Overview
      • 15.2.9.5. SWOT Analysis

List of Tables

  • Table 01: Global Macular Degeneration Treatment Market Pipeline Analysis Phase I
  • Table 02: Global Macular Degeneration Treatment Market Pipeline Analysis Phase II
  • Table 03: Global Macular Degeneration Treatment Market Pipeline Analysis Phase III
  • Table 04: Regulatory Scenario, by Region/Globally
  • Table 05: Key Mergers & Acquisitions
  • Table 06: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 07: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 08: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 09: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 10: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 11: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 12: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 13: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 14: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 15: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 16: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 17: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 18: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 19: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 20: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 21: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 22: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 23: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 24: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 25: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 26: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 27: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 28: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 29: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026

List of Figures

  • Figure 01: Global Macular Degeneration Treatment Market Snapshot
  • Figure 02: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016-2026
  • Figure 03: Global Macular Degeneration Treatment Market Value Share, by Disease Indication (2017)
  • Figure 04: Global Macular Degeneration Treatment Market Value Share, by Drug Class (2017)
  • Figure 05: Global Macular Degeneration Treatment Market Value Share, by Distribution Channel (2017)
  • Figure 06: Global Macular Degeneration Treatment Market Value Share, by Region (2017)
  • Figure 07: AMD Prevalence with Key Countries
  • Figure 08: Clinical Trial Analysis Status by Phase
  • Figure 09: Clinical Trial Analysis by Status
  • Figure 10: Clinical Trial Analysis by Completion and Termination Rate
  • Figure 11: Clinical Trial Analysis by Region
  • Figure 12: Global Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 13: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Wet AMD, 2016-2026
  • Figure 14: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Dry AMD, 2016-2026
  • Figure 15: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Other Indications, 2016-2026
  • Figure 16: Global Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2018-2026
  • Figure 17: Global Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 18: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Anti-Vascular Endothelial Growth Factor, 2016-2026
  • Figure 19: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2016-2026
  • Figure 20: Global Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026
  • Figure 21: Global Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 22: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Hospitals, 2016-2026
  • Figure 23: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Ophthalmic Clinics, 2016-2026
  • Figure 24: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Ambulatory Surgical Centers, 2016-2026
  • Figure 25: Global Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 26: Macular Degeneration Treatment Market Value Share Analysis, by Region, 2017 and 2026
  • Figure 27: Macular Degeneration Treatment Market Attractiveness Analysis by Region, 2018-2026
  • Figure 28: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 29: North America Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 30: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026
  • Figure 31: North America Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 32: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2018-2026
  • Figure 33: North America Macular Degeneration Treatment Market Value Share Analysis, , by Distribution Channel, 2018-2026
  • Figure 34: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 35: North America Macular Degeneration Treatment Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 36: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 37: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 38: Europe Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 39: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026
  • Figure 40: Europe Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 41: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2018-2026
  • Figure 42: Europe Macular Degeneration Treatment Market Value Share Analysis, , by Distribution Channel, 2018-2026
  • Figure 43: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 44: Europe Macular Degeneration Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 45: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 46: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 47: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 48: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026
  • Figure 49: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 50: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2018-2026
  • Figure 51: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, , by Distribution Channel, 2018-2026
  • Figure 52: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 53: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 54: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 55: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 56: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 57: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026
  • Figure 58: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 59: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2018-2026
  • Figure 60: Latin America Macular Degeneration Treatment Market Value Share Analysis, , by Distribution Channel, 2018-2026
  • Figure 61: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 62: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 63: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 64: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 65: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 66: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2018-2026
  • Figure 67: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 68: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2018-2026
  • Figure 69: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2018-2026
  • Figure 70: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 71: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 72: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Country, 2018-2026